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Abstract 
Research into naturally occurring antimicrobial substances has yielded effective treatments. One 
area of interest is peptides and proteins produced by invertebrates as part of their defence system, 
including the contents of mollusc mucous. Mucous produced by the African giant land snail, 
Achatina fulica has been reported to contain two proteins with broad spectrum anti-bacterial 
activity. Mucous from the brown garden snail, Helix aspersa appears to have skin regeneration 
properties. This study sought to investigate the antimicrobial properties of H.aspersa mucous. 
Mucous was collected from H.aspersa snails, diluted in PBS and centrifuged, with the supernatant 
tested against a wide range of organisms in a disc diffusion antimicrobial assay. This was followed up 
with comparative experiments involving A.fulica , including bacteriophage assays. Mucous from both 
species of snail was passed through a series of protein size separation columns in order to determine 
the approximate size of the antimicrobial substance. Electrophoresis was also carried out on the 
H.aspersa mucous.    
Results indicated that H.aspersa mucous had a strong antibacterial effect against several strains of 
Pseudomonas aeruginosa and a weak effect against Staphylococcus aureus. Mucous from A.fulica  
also inhibited the growth of  S.aureus, but the  broad spectrum of activity reported by other workers 
was not observed. Antimicrobial activity was not caused by bacteriophage. Size separation 
experiments indicated that the antimicrobial substance(s) in H.aspersa were between 30 and 100 
kDa. Electrophoresis revealed two proteins in this region – 30-40 kDa and 50-60kDa. These do not 
correspond with antimicrobial proteins previously reported in A.fulica. 
This study found one or more novel antimicrobial agents in H.aspersa mucous, with a strong effect 
against P.aeruginosa . 
2 
 
Key words: antimicrobial, Pseudomonas aeruginosa, Helix aspersa, mucous  
Introduction 
The discovery of antibiotics in the middle of the 20th century significantly decreased the morbidity 
and mortality associated with infectious diseases. However, the ability of microorganisms to develop 
resistance to antimicrobial agents has been of concern since the first report of reduced susceptibility 
to penicillin of Streptococcus pneumoniae in 1965 1.  This has now become a major public health 
issue, noted by the Chief Medical Officer for England in her 2013 annual report 2 and the subject of a 
World Health Assembly meeting which developed a global plan of action 3.    
Since many of the first antibiotics were naturally occurring substances, researchers have continued 
to investigate anecdotal evidence and folklore to find new antimicrobial agents. This has led to the 
discovery that, for example, a topical preparation of the essential oil ‘tea tree’ (Melaleuca 
alternifolia) from Australia has antiseptic and anti-inflammatory properties 4, and that the Chinese 
herbal remedy qinghaosun (artemisinin) derived from Artemisia annua is an effective anti-malarial 5. 
Copper, which was advocated by Hippocrates for the treatment of leg ulcers, is microbicidal and 
therefore has a useful role in infection control when incorporated into frequently touched surfaces 
in hospitals 6.  
One area of current interest is antimicrobial peptides (AMPs) in invertebrates. These are relatively 
small ( 5-15 kDa ) molecules which are part of the animal’s natural defence system 7 Examples which 
have been characterised from molluscs include defensins, mytilins, myticins and mytimacins 8,9 .  
Most of the AMPs described to date are found in the haemolymph of the invertebrate and the 
literature suggests they have activity against an eclectic mix of microorganisms including bacteria, 
viruses and protozoa 8.   
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A range of internal AMPs have been found in gastropods, but it is also likely that their external 
secretions would have components affording protection against potential pathogens, in a similar 
manner to the antimicrobial substances found in the mucous of fish and amphibians 10, 11.  . 
Terrestrial slugs and snails produce mucous which performs a variety of functions, including 
facilitating movement along the ground, communication and a non-specific, defensive response to 
physical or chemical irritation 12.  
The antimicrobial properties of the mucous collected from African giant land snails ( Achatina fulica) 
were first described in the 1980s, by researchers in Japan 13, 14 . These authors reported finding that 
when mucous was mixed with water and centrifuged, the resulting supernatant exhibited 
antimicrobial activity in a standard disc diffusion assay 13. Biochemical investigations of the nature of 
the active ingredient led to the conclusion that it is a glycoprotein 13  of around 140 - 160,000 Da 14, 15 
, which they subsequently named  ‘Achacin’ 15.  They stated that Achacin inhibited the growth of a 
representative selection of Gram positive and Gram negative bacteria, namely Staphylococcus 
aureus, Bacillus subtilis, Escherichia coli and Pseudomonas aeruginosa 13, 14, 15. From their 
investigations of its mode of action, they concluded that Achacin is only effective against actively 
growing and dividing organisms 15.  
This work does not appear to have been followed up extensively, although Zhong et al. 16 found a 
smaller peptide (9700 Da) in A.fulica mucous, which they characterised as an AMP in the mytimacin 
family and therefore called ‘Mytimacin-AF’. This was reported to have antimicrobial activity against 
Staphylococcus aureus, several  Bacillis spp., Klebsiella  pneumoniae and Candida albicans 16 , but to 
be particularly effective in reducing growth of S.aureus. The authors did not discuss its possible 
mode of action or reasons for its selectivity. Similarly, Santana et al. 17 tested the in vitro activity of 
neat A.fulica mucous against C.albicans, E.coli, S.aureus, S.epidermidis, Fusarium spp. and Salmonella 
spp.. They reported that it inhibited the growth of S.aureus and S.epidermidis, but did not mention 
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the results for the assays using the other organisms. In a separate set of experiments, Santana et al. 
17 formulated mucous into a wound dressing preparation, which was applied to skin lesions on the 
backs of rats. They presented histological results suggesting that the A.fulica mucous promoted 
wound healing 17 , but specific antimicrobial activity in vivo was not reported.  
The brown garden snail, Helix aspersa has been used in human medicine since antiquity: Hippocrates 
recommended snail mucus for the treatment of protocoele whilst Pliny stated that snail 
preparations could be employed in everything from childbirth to nosebleeds 18.  Recently, anecdotal 
reports of generic skin regeneration properties of the mucous from H. aspersa have been explored 
19; this has resulted in the commercial production of a topical preparation 20 which is claimed to have 
“wound healing” as well as anti-ageing properties. Tsoutsos et al. 19 tested the preparation on burns 
patients and while they noted that a range of opportunistically pathogenic bacteria were isolated 
from swabs collected from the wounds before treatment, this was not followed up with culture of 
post treatment specimens.  Thus, the specific antimicrobial properties of H.aspersa mucous do not 
appear to have been researched.   
Therefore the aim of this study was to investigate the antimicrobial properties of mucous from the 
common garden snail Helix aspersa and to characterise any active ingredient(s) discovered. Since 
most of the previously published work in this area related to Achatina fulica, analysis of mucous 
from this species of mollusc was also included for comparison.    
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Method 
Snail care and mucous collection  
Helix aspersa 
Twenty snails were collected from the wild and kept indoors in a clear plastic tank (35 x 22 x 14cm) 
at room temperature (~210C) and ambient light. They were fed on lettuce leaves, cucumber, carrots 
and apples and provided with water, along with a source of calcium. The tanks were cleaned weekly.  
Mucous production was encouraged by taking each individual snail and gently stimulating it with a 
cotton swab moistened in phosphate buffered saline (PBS). The resulting secretions were collected 
using 10ml plastic Pasteur pipettes and pooled into one aliquot. The mucous was left to settle at 
room temperature for 1-2hours before dilution at 1:3 in PBS and centrifugation at 4500rpm for 20 
minutes. The supernatant was used in subsequent investigations. 
Achatina fulica  
Four captive bred juvenile snails were made available for this study courtesy of Dr Sally Willliamson, 
Liverpool John Moores University. They were maintained under the same conditions as the 
H.aspersa snails, except that the tank was slightly deeper (35 x 22 x 21cm) and their diet was 
cucumber and butternut squash. Mucous production and collection was carried out in a similar 
manner to that described above for the garden snails.  The mucous was diluted in PBS and processed  
to obtain supernatant as described above. 
 
Initial antimicrobial assay 
6 
 
Supernatant from the 1:3 diluted Helix aspersa mucous was tested against a range of organisms, 
namely: Candida albicans ATCC 10231, Escherichia coli NCTC 10385, Klebsiella pneumoniae NCTC 
11228, Proteus mirabilis NCTC 10823, Pseudomonas aeruginosa NCIMB 10548, Pseudomonas 
aeruginosa, NCTC 8626, Staphylococcus aureus NCTC 10788 and Streptococcus pyogenes NCIMB 
13285, plus  ‘in house’ isolates of Acinetobacter spp. (R4474),  Salmonella abony  and Serratia 
marcescens. 
Organisms were grown up overnight in broth cultures of Tryptone Soy Broth (TSB), ( Oxoid, 
Basingstoke, Hampshire, UK) and diluted to between 10 6 and 10 7 colony forming units ( cfu) mL -1 
(verified by viable count).  A 100L aliquot of the bacterial suspension was spread onto an 
Isosensitest agar (ISA) plate (Oxoid, Basingstoke, Hampshire,UK) and left to dry for 15 minutes. Blood 
agar - prepared using Blood agar base No. 2  (Oxoid Basingstoke, Hampshire, UK) plus 7% blood - 
was substituted for ISA in the Streptococcus pyogenes assay and Sabouraud Dextrose Agar  (SDA) 
(Oxoid, Basingstoke, Hampshire, UK) was used to test the activity against C.albicans. Three sterile 
paper assay discs ( 5 mm diameter) were applied to each plate and 50L of the mucous supernatant 
was added to two of them, while the third was treated with 50L PBS as a control. Plates were 
incubated at 370C for 18-24 hours before being read. Zones of inhibition were recorded in mm. For 
most of the organisms tested the assay was performed twice and a mean zone of inhibition was 
calculated.  For the two strains of P.aeruginosa, the assay was performed four times, generating 
eight readings from which the mean was taken.  
After analysis of the results from the initial antimicrobial assay, the effect of H. aspersa mucous on 
Pseudmonas aeruginosa was investigated in more detail and a third strain, namely Pseudomonas 
aeruginosa NCTC 10662 was included. At this point, the A. fulica mucous was introduced into the 
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study for comparison and both types of mucous were also tested against Escherichia coli  NCTC 
10385, Staphylococcus aureus NCTC 10788 and Candida albicans ATCC 10231. 
Biochemical analysis  
An aliquot of 1:3 diluted H.aspersa mucous supernatant was analysed for protein content using the 
Biuret method. The result was obtained in g/L which was then calculated as mg/mL for the undiluted 
mucous.        
Size separation assays 
Approximately 500L aliquots of the mucous supernatant were processed in a series of Vivaspin 500 
protein size separator columns (Sartorious, Epsom, Surrey, UK) at 1,000 kDa, 100 KDa, 30 kDa and 10 
KDa following the manufacturer’s instructions – including pre-rinsing in distilled water to remove 
sodium azide. The resulting filtrate and concentrate were each tested in the antimicrobial assay 
against the three P.aeruginosa strains, S.aureus, E.coli and C. albicans. Each plate was set up with 3 
test discs and 1 PBS control. All experiments were repeated at least once (i.e. at least 6 replicates); 
results were scored qualitatively.  
Electrophoresis 
H.aspersa mucous was processed through the 1, 000 kDa size separation column and the resulting 
filtrate was analysed by SDS-PAGE electrophoresis, by adding a 25 L aliquot ( in duplicate)  to a 4-
12% gradient NuPAGE Novex Bis-Tris Protein gel (Life Technologies, Paisley, UK). The gel was run in   
NuPAGE MOPS SDS Running Buffer at 200 V for 50 minutes. The Novex Sharp Pre-stained Protein 
Standard marker LC5800 (Life Technologies, Paisley, UK) was included in the run. The gel was then 
stained with 0.25% Coomassie Blue R250 dissolved in 50% methanol, 10% acetic acid for 2 hours and 
destained overnight in several changes of solution containing 5% methanol, 7.5% acetic acid. 
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Bacteriophage screening assay 
Aliquots of the 1:3 diluted mucous from H.aspersa and A.fulica were screened for the presence of 
bacteriophage using a method modified from that described by Adams 21 and tested against the 
following organisms:  Candida albicans ATCC 10231, Escherichia coli NCTC 10385, Klebsiella 
pneumoniae NCTC 11228, Proteus mirabilis NCTC 10823, Pseudomonas aeruginosa NCIMB 10548, 
Pseudomonas aeruginosa, NCTC 8626, Pseudomonas aeruginosa, NCTC , Staphylococcus aureus 
NCTC 10788 and Streptococcus pyogenes NCIMB 13285, plus  ‘in house’ isolates of Acinetobacter 
spp. (R4474),  and Serratia marcescens. 
For each organism 100µL of an overnight broth culture was spread onto a Tryptone Soya Agar (TSA) 
plate ( Oxoid, Basingstoke, UK). A 5µL drop of each type of mucous was spotted on the plate, which 
was allowed to dry before incubating for 24 hours at 37°C. An enrichment culture method was also 
used, where 100µL of host bacteria and 5µL of mucous were inoculated into 10ml TSB and incubated 
at 370C for 18 hours. After this, approximately 1mL was passed through a 0.45µm filter to remove 
the bacteria and 5µL of the resulting suspension spotted onto fresh bacterial lawns and the plates 
incubated for 24 hours at 370C. All plates were examined for any signs of clearing.    
 
Results 
Small (between 500 L and 1mL), but sufficient quantities of mucous were successfully collected 
from the H.aspersa and the A.fulica snails each time experiments were conducted. The viscosity of 
the mucous varied between batches harvested on different days.  
The results of testing the supernatant of the H.aspersa mucous after 1:3 dilution in PBS against a 
range of organisms are shown in Table 1. Clear, measurable zones of inhibition were obtained with 
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the two P.aeruginosa strains (Table 1, Figure 1), but no effect was observed for any of the other 
microorganisms.  
Tables 2a and 2b indicate the outcomes from protein size separation experiments. They show that 
the antimicrobial activity was found in the filtrate from the 1, 000 kDa column for both types of 
mucous and against the two organisms where zones of inhibition were observed.  For the H.aspersa 
mucous, these results located the protein(s) of interest at between 30 and 100 kDa in size (Table 2a), 
while the active ingredient in A.fulica mucous appeared to be around 100 kDa (Table 2b).  When 
testing H.aspersa mucous against the strains of P.aeruginosa, clear zones of inhibition were 
obtained, as illustrated by Figure 2.  The activity against S.aureus found in both types of mucous 
became apparent after passing mucous through the 1, 000 kDa, but did not result in clear zones 
(Figures 3and 3b).   
The total protein content of the H.aspersa mucous diluted 1:3 was 1.6 g/L. This was calculated to be 
4.8mg/mL protein in neat mucous. 
The electrophoresis revealed eight protein bands in the H.aspersa mucous, including one between 
50 and 60 kDa and one at approximately 35 kDa ( Figure 4). Additional bands were noted at >260, 
20, 15, 10, 12 and <10 kDa.  
No bacteriophage activity was found in the H.aspersa or A.fulica mucous against the target 
organisms tested in either the direct or enrichment assay (Table 3). Although there was some faint 
clearing observed in the direct assay with Serratia marcescens, on further investigative sampling, no 
active bacteriophage were isolated.  
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Discussion 
This study has shown that the mucous from the common brown garden snail, Helix aspersa, has a 
demonstrable antimicrobial activity against several strains of Pseudomonas aeruginosa. The 
bacteriophage assay results indicated that this is not an effect caused by bacteriophage in the 
mucous. Previous studies on the antimicrobial activity of snail mucous have not tested for this, 
although bacteriophages have recently been shown to adhere to the mucous from a wide of 
organisms, including humans, thus contributing to the antimicrobial response 22.   While the 
concentration of the active ingredient(s) was not ascertained, clear and repeatable zones of 
inhibition were observed when the mucous was diluted in PBS but not subject to any other 
preparation (Figure 1). The diameter of the assay disc was 5mm, which meant that the specific 
antimicrobial effect accounted for over 6mm in the recorded zones (Table 1). This effect against 
P.aeruginosa was initially found in the unseparated mucous supernatant and subsequent 
investigations indicated the active ingredient to be between 30 and 100 kDa. As Table 2a shows, 
antimicrobial effect was found in the concentrate after the 30 kDa size separation and the filtrate 
after the 100kDa step.  Electrophoresis results confirmed that two proteins were present in 
H.aspersa mucous in this size region – one between 50 and 60 kDa and one approximately 35kDa in 
size (Figure 4). Resistance by P.aeruginosa to currently available antimicrobials is an increasing 
problem in clinical practice 23 . Therefore this is a significant result, which does not appear to have 
been reported previously.   
In contrast,  A.fulica mucous was not found to have activity against any of the strains of P.aeruginosa 
included in this study, either in the unseparated form or after any of the size separation processes. 
This was unexpected, since it contradicts previously reported studies 13, 14 , which apparently showed 
a strong effect against this bacterium. It is not clear why this should be the case, but the present 
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findings appear to concur with those of Santana et al. 17 , who did not report any results from their 
tests using P.aeruginosa ATCC 1024.  
During the study, it was discovered that the use of the 1, 000 kDa column was a useful concentration 
step; the active ingredient(s) were retained and it enhanced the effect of both types of mucous 
against S.aureus. (Tables 2a and 2b; Figures 3a and 3b).  By using this processing prior to the 
antimicrobial assays, it was found that H. aspersa mucous also had an inhibitory effect against 
Staphylococcus aureus, although it was less marked (Figure 3a). A similar effect was noted with the 
A.fulica mucous (Table 2b, Figure 3b). The fact that A.fulica mucous was found to be active against S. 
aureus does concur with previous work 13, 14, 15, 16, 17 , although none of the other authors report the 
relatively weak effect found in the present study. However, apart from Santana et al. 17 , all describe 
isolating the active ingredient  - i.e. Achacin 13, 14, 15 or Mytimycin-AF  16 - before testing it against the 
bacteria. Santana et al. 17 , seem to have followed a very similar antimicrobial assay method to that 
employed in the present study, with the exception of their use of Mueller – Hinton agar instead of 
ISA and wells in the agar instead of discs. They reported that an aliquot of 5L of A.fulica mucous did 
not inhibit growth of S. aureus, but that an effect was noted at 10L and 20L 17. They did not 
attempt to separate out the protein content or concentrate the mucous in any way, so this supports 
the idea that the effect is enhanced when more of the active ingredient is available to interact with 
the bacterium.    
The H.aspersa mucous was not found to be effective against a range of other bacteria or Candida 
albicans . Initially this finding was rather unexpected, since components of A.fulica mucous have 
previously been reported to inhibit the growth of E.coli 15, 16 , a number of Bacillus species 13, 16 and  
K.pneumoniae 16 as well as C.albicans 16 . Extrapolating from the literature it seemed possible that 
H.aspersa mucous might have a similar broad spectrum of activity, which is why a variety of 
organisms were tested in the initial antimicrobial assay. However, this study was not able to 
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reproduce the antimicrobial effect of A.fulica mucous against E.coli, C.albicans or P.aeruginosa. It is 
possible that this discrepancy is due to variations in methodology or the strains of organisms used. 
However, Santana et al. 17 also tested A.fulica mucous using a simple method (involving whole 
mucous rather than particular fractions) against a range of organisms and similarly reported an 
effect for Staphylococcus species only. They used different type culture collection organisms for 
E.coli, P.aeruginosa and indeed S. aureus to the present study 17 , which shows that strain variation is 
unlikely to be the explanation. By coincidence, they used the same C.albicans (ATCC 10231) and 
found the same (negative) result. In this study, size separation was used to isolate and concentrate 
the active ingredient (see below), but no effect was observed when A.fulica mucous was tested 
against E.coli, P. aeruginosa or C.albicans (Table 2b). This all suggests that the finding of a limited 
activity for H.aspersa mucous is likely to be genuine. 
The H.aspersa mucous contained 4.8 mg/mL protein, which is comparable to the 4mg/mL reported 
by Iguchi et al. 13 in A.fulica mucous.  The size separation experiments (Table 2a) indicated that there 
were no proteins of less than 30 kDa active against the microorganisms under test in this study. This 
size and specificity means that it is unlikely that the antimicrobial activity is associated with 
lysozymes, which are known to be present in snails and their mucous 24. Invertebrate lysozymes are 
usually small proteins with molecular weight of around 15kDa.  It also indicates that an antimicrobial 
compound analogous to Mytimacin-AF 16 or any other AMP  8  is unlikely to be present.  In this study, 
the substance which was active against S.aureus in A.fulica was present in both the filtrate and the 
concentrate after separation in the 100 kDa column. This was a surprise, since Achacin is reported to 
be a protein of 160 kDa, formed of two subunits of 70-80 kDa each 14 . It would be expected that 
only the whole molecule would be active in the antimicrobial assays and that the effect would 
therefore have been seen solely in the 100kDa concentrate, but it was not (Table 2b ).  
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Size separation experiments indicated that the antimicrobial effect in the H.aspersa mucous was due 
to one or more proteins of between 30 and 100kDa in size (Table 2a) and electrophoresis revealed 
no clear band present in 110-160 kDa region (Figure 4).  Bands were visible at between 30 and 40 
kDa and between 50 and 60 kDa (Figure 4), but they were comparatively faint, suggesting that these 
proteins were present in relatively low concentrations. It therefore could be that H.aspersa mucous 
does indeed contain an antimicrobial protein which corresponds to Achacin and is of a similar size, 
but that it is was not detectable by the biochemical methods used in this study. This idea is 
supported by the fact that mucous from both species of snail produced a similar, albeit relatively 
weak, antimicrobial effect against S. aureus in the assay used here (Figures 3 a and 3 b) and Achacin 
is reported to be effective in killing this Gram positive coccus 15.  However the ingredient active 
against S.aureus in the H.aspersa mucous was clearly within the 30-100 kDa range and it is possible 
that one of the two proteins identified in this region are responsible for the anti-staphylococcal 
effect.   
The activity of the H.aspersa mucous against P.aeruginosa appears to be stronger and there are two 
possible explanations for this. One is that there is an Achacin-like protein and that it interacts 
differently with the P.aeruginosa. This is plausible since Otsuka-Fuchin et al. 15 suggested that 
Achacin could be targeting cell wall synthesis and P.aeruginosa is a Gram negative bacillus, with a 
different cell wall composition to S.aureus. Alternatively, since antimicrobial agents exploit 
peculiarities in prokaryotic metabolism, this protein could be interfering with a species specific 
pathway. The other possibility is that one or both of the two smaller proteins (30-40 kDa and 50-
60kDa in size) identified as potential antimicrobials in H.aspersa mucous are affecting the 
P.aeruginosa. The strength of the effect on bacteria of this species (Figures 1a, 1b and 2) could be 
because the two substances interact to achieve the anti-microbial effect.  Further work to fully 
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characterise the active ingredient(s) and exploration of the specific antimicrobial effects should 
clarify this 
 Although the results presented here were repeatable, it was not possible to confirm many of the 
previously published findings with A. fulica. This could be due to the low concentration of the active 
ingredient(s) in the mucous as it was collected and processed in this study. It is therefore possible 
that H.aspersa has a broader spectrum of activity than found here, analogous to that reported by 
other authors for A.fulica. Once the active ingredient has been fully characterised, tests with the 
wide range of microorganisms used in initial antimicrobial assay in this study could be repeated.  
Further work would include obtaining a profile of the protein content for example using matrix 
assisted laser desorption/ionisation (MALDI) and then isolating fractions of the mucous protein 
without denaturing them -using for example high performance liquid chromatography (HPLC) or 
native gel electrophoresis; the individual fractions could then be put into the antimicrobial assay in 
order to determine the exact size of the active ingredient(s). Once this was known, the protein could 
be sequenced and fully characterised which would allow elucidation of its site and mode of action 
against relevant microorganisms.  
In this study, H.aspersa  mucous was found to be equally effective against three laboratory strains of 
P.aeruginosa. The next phase therefore would be to test it (in vitro) against clinical isolates. If this 
proves successful, then the effectiveness of the topical preparation, such as the one already 
available commercially  19 could be explored.   
The antimicrobial activity in H.aspersa mucous appears to be caused by one or more novel 
substances with molecular weight between 30 and 100 kDa. There is a particularly strong inhibitory 
effect against P.aeruginosa  and further investigation is warranted.   
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Table 1: Mean zones of inhibition in antimicrobial assay with 1:3 diluted H.aspersa mucous 
                  Mean  zone of  Inhibition, mm (SD) 
Organism PBS control Mucous supernatant 
Staphylococcus aureus NCTC 10788 0 0 
Streptococcus pyogenes NCIMB 13285 5.51 5.5 
Candida albicans ATCC 10231 0 0 
Escherichia coli NCTC 10385 0 0 
Klebsiella pneumonia NCTC 11228 0 0 
Salmonella abony 2 0 0 
Proteus mirabilis2 0 0 
Acinetobacter spp.2 0 0 
Serratia marcescens 2 0 0 
Pseudomonas aeruginosa 8626 0 11.12 ( 2.57) 
Pseudomonas aeruginosa 10548 0 11.63 ( 1.52) 
1 non-specific zone of haemolysis noted in both control and test plates; 2 ‘in house’ isolates with no 
type culture collection identification  
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Table 2a: The effect of passing H.aspersa mucous through protein size separator columns on the 
retention of antimicrobial activity , indicating zone of inhibition ( +) or no zone of inhibition (-). 
 10kDa column 30kDa column 100 kDa column 1,000 kDa column 
 Filtrate Concentrate Filtrate Concentrate Filtrate Concentrate Filtrate Concentrate 
E. coli      
NCTC 10385 
- - - - - - - - 
C. albicans 
ATCC 10231 
- - - - - - - - 
S. aureus 
NCTC 10788 
- + - + + - + - 
P.aeruginosa 
NCTC 8626 
- + - + + - + - 
P.aeruginosa 
NCIMB 10548 
- + - + + - + - 
P.aeruginosa 
NCTC 10662 
- + - + + - + - 
In all cases, PBS control discs gave a zone size of 0mm.   
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Table 2b : The effect of passing A.fulica mucous through protein size separator columns on the 
retention of antimicrobial activity, indicating zone of inhibition ( +) or no zone of inhibition (-). 
 10kDa column 100 kDa column 1,000 kDa column 
 Filtrate Concentrate Filtrate Concentrate Filtrate Concentrate 
E. coli     
NCTC 10385 
- - - - - - 
C.albicans 
ATCC 10231 
NT NT NT NT - - 
S.aureus 
NCTC 10788 
- - + + + - 
P.aeruginosa 
NCTC 8626 
- - - - - - 
P.aeruginosa 
NCIMB 10548 
- - - - - - 
P.aeruginosa 
NCTC 10662 
- - - - - - 
In all cases, PBS control discs gave a zone size of 0mm. ; NT = not tested 
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Table 3: Results from direct and enriched phage assays against a range of target organisms   
 
 H.aspersa mucous A.fulica mucous 
Organism 
 
Direct phage 
assay 
Enriched 
phage 
assay 
Direct phage 
assay 
Enriched 
phage assay 
Pseudomonas aeruginosa NCIMB 
10548 
No zone No zone No zone No zone 
Pseudomonas aeruginosa NCTC 8626 No zone No zone No zone No zone 
Pseudomonas aeruginosa NCTC 10662 No zone No zone No zone No zone 
Staphylococcus aureus NCTC 10788 No zone No zone No zone No zone 
Streptococcus pyogenes NCIMB 13285 No zone No zone No zone No zone 
Proteus mirabilis NCTC 10823 No zone No zone No zone No zone 
Klebsiella pneumonia NCTC 11228 No zone No zone No zone No zone 
Escherichia coli NCTC 10385 No zone No zone No zone No zone 
Serratia marcescens No zone1 No zone No zone No zone 
Acinetobacter R4474 No zone No zone No zone No zone 
Candida albicans ATCC 10231 No zone No zone No zone No zone 
1Some signs of clearing but no plagues were obtained when the zone was isolated. 
 
 
 
22 
 
 
 
Figure 1: Zones of inhibition observed after overnight incubation of 50l Helix aspersa mucous 
(diluted 1:3)  on 5mm disc on lawn of 1a P.aeruginosa NCIMB10548 and 1b P.aeruginosa NCTC8626 
 
Figure 2 Zones of inhibition with P.aeruginosa 10548 after testing the filtrate obtained from passing 
the H.aspersa mucous though a 100 kDa column.  
 
Figure 3 Zones observed in the assay using filtrate from 1,000kDa size separation column against 
S.aureus for a) H.aspersa mucous and b) A.fulica mucous, showing defined ring with growth of 
organism within it. 
 
Figure 4 Results obtained from SDS-PAGE electrophoresis using the filtrate obtained from passing 
H.aspersa mucous through a 1, 000 kDa size separation column. 
